- $389.83m
- $351.37m
- $303.91m
- 57
- 46
- 100
- 76
Annual balance sheet for Angiodynamics, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | 2024 May 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 54.4 | 48.2 | 28.8 | 44.6 | 76.1 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 34.2 | 35.4 | 52.3 | 52.8 | 50 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 153 | 141 | 143 | 164 | 193 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 38.5 | 46.5 | 52 | 49.5 | 41.5 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 594 | 561 | 553 | 533 | 318 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 51.4 | 57.6 | 74.3 | 83.8 | 91.2 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 139 | 122 | 128 | 154 | 112 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 455 | 439 | 424 | 378 | 206 |
Total Liabilities & Shareholders' Equity | 594 | 561 | 553 | 533 | 318 |
Total Common Shares Outstanding |